|
|
|
|
|
|
|
M T Wed Th F |
|
16 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outing myself as a science nerd, I was fascinated by a study out this morning in Nature. Stanford researchers replaced the cortex of a mouse — fully half of its brain by volume — with human cells. The researchers plan to use it as a model for diseases like frontotemporal dementia and genetic forms of autism that have been impossible to study in a living brain. I have the details here. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Karen Weintraub
|
|
“There is now a mouse, the cortex of which is filled with human cells. We can’t quite call that a mouse, and we certainly can’t... |
| |
|
|
|
 |
|
Novo\'s new look (Mads Claus Rasmussen/Ritzau Scanpix/Sipa via AP Images) |
|
|
|
by Andrew Dunn
|
Anthropic is deepening ties with the Danish drugmaker Novo, in the latest gain for the tech giant's life sciences business. In a Wednesday release... | |
|
|
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about VaxThera, Sironax, Circle Pharma, Nutshell Therapeutics, Evopoint and Sensorion. Gilead’s HIV PrEP pact in Latin America: The California drugmaker said it... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Novartis has scrapped development of a Phase 2 treatment candidate for amyotrophic lateral sclerosis, Endpoints News has learned. The Swiss pharma giant is ending work... | |
|
|
|
|
|
